Bristol Myers Squibb names new Head of Development
The new appointee has over twenty years of experience in…
The new appointee has over twenty years of experience in biopharma and extensive senior expertise in oncology.
List view / Grid view
The new appointee has over twenty years of experience in…
The new appointee has over twenty years of experience in biopharma and extensive senior expertise in oncology.
Topline data from a Phase II trial signify a significant…
Topline data from a Phase II trial signify a significant step forward for ENHERTU® (trastuzumab deruxtecan) in its potential to provide a new option in HER2 expressing cancers.